Talimogene laherparepvec: First in class oncolytic virotherapy

• Published in: Human vaccines & immunotherapeutics Vol. 14; no. 4; pp. 839 - 846
• Main Authors: Conry, Robert M., Westbrook, Brian, McKee, Svetlana, Norwood, Timothy Graham
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03.04.2018; Taylor & Francis Group
• Subjects: Animals; Antigens, Neoplasm - immunology; Dendritic Cells - immunology; granulocyte-macrophage colony-stimulating factor; granulomatous dermatitis; herpes simplex viral type i; Herpesvirus 1, Human - immunology; Humans; immune checkpoint blockade; Immunotherapy - methods; melanoma; Oncolytic Virotherapy - methods; oncolytic virus; Oncolytic Viruses - immunology; Product Review; Randomized Controlled Trials as Topic; talimogene laherparepvec; Talimogene laherparepvec; herpes simplex viral type I; granulomatous dermatitis; oncolytic virus; granulocyte-macrophage colony-stimulating factor; melanoma; immune checkpoint blockade

Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherpar...